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Abstract
Rationale Both glutamate and serotonin (5-HT) play a key
role in the pathophysiology of emotional biases. Recent
studies indicate that the glutamate N-methyl-D-aspartate
(NMDA) receptor antagonist ketamine and the 5-HT recep-
tor agonist psilocybin are implicated in emotion processing.
However, as yet, no study has systematically compared their
contribution to emotional biases.
Objectives This study used event-related potentials (ERPs)
and signal detection theory to compare the effects of the
NMDA (via S-ketamine) and 5-HT (via psilocybin) receptor
system on non-conscious or conscious emotional face pro-
cessing biases.
Methods S-ketamine or psilocybin was administrated to two
groups of healthy subjects in a double-blind within-subject
placebo-controlled design. We behaviorally assessed objec-
tive thresholds for non-conscious discrimination in all drug
conditions. Electrophysiological responses to fearful, happy,
and neutral faces were subsequently recorded with the face-
specific P100 and N170 ERP.
Results Both S-ketamine and psilocybin impaired the
encoding of fearful faces as expressed by a reduced N170
over parieto-occipital brain regions. In contrast, while S-
ketamine also impaired the encoding of happy facial expres-
sions, psilocybin had no effect on the N170 in response to
happy faces.
Conclusion This study demonstrates that the NMDA and 5-
HT receptor systems differentially contribute to the structur-
al encoding of emotional face expressions as expressed by
the N170. These findings suggest that the assessment of
early visual evoked responses might allow detecting phar-
macologically induced changes in emotional processing
biases and thus provides a framework to study the patho-
physiology of dysfunctional emotional biases.
Keywords Glutamate . Serotonin . Ketamine . Psilocybin .
Emotional processing biases . Event-related potential .
Visual awareness . Non-conscious . Conscious
Introduction
Emotional processing including the recognition of other
people’s feelings from their facial expression is fundamental
to social interaction and behavior. The importance of face
recognition in the human social functioning is shown by the
fact that emotional faces increase neuronal activity relative
to neutral faces in specific brain areas. For example, in-
creased brain responses to emotional faces have been ob-
served in visual face-selective areas of the brain, even when
emotional faces were masked to prevent visual awareness
(Pegna et al. 2008; Smith 2011). Thus, modulation of face-
specific responses in the visual cortex by emotional expres-
sions might correspond to a fundamental regulatory role of
basic emotional signals associated with social appraisal and
cognition (Schultz et al. 2003; Singer et al. 2004).
Emotional face processing can be modulated by seroto-
nin (5-hydroxytryptamine, 5-HT). For example, acute ad-
ministration of the selective serotonin reuptake inhibitor
(SSRI) citalopram facilitated recognition of fear and happy
facial expressions in the citalopram treated group relative to
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the placebo group (Bhagwagar et al. 2004; Browning et al.
2007; Harmer et al. 2003). In a later study, repeated admin-
istration of citalopram in healthy subjects increased the
relative processing of positive to negative emotional faces
in a manner directly opposite to the negative biases previ-
ously described in depression (Harmer et al. 2004). Both
findings suggest important neuropsychological evidence of
a possible mechanism of action of antidepressant drugs
(Nathan et al. 2003). The findings are consistent with other
studies examining the neurophysiological mechanisms un-
derlying antidepressant effects on emotional processing. In
these studies, acute citalopram administration was shown to
inhibit visual evoked electrophysiological responses to un-
pleasant stimuli, while it facilitates visual responses to
pleasant stimuli (Kemp et al. 2003, 2004; Nathan et al.
2003). These studies suggest that this capacity to shift
emotional biases—increasing the response to positive and
decreasing the response to negative stimuli—seems not only
to be characteristic for the action of SSRI on emotional pro-
cessing but seems also to be highly relevant for the treatment
of emotional biases found in depression (Harmer 2008).
In addition, emotional face processing can also be affect-
ed by glutamatergic manipulation. Specifically, a functional
imaging study in healthy subjects showed that the visual
activity in response to fearful faces is abolished under the
influence of the glutamate N-methyl-D-aspartate (NMDA)
receptor antagonist ketamine (Abel et al. 2003). Taken to-
gether, these findings suggest that acute manipulations of
the serotonergic and glutamatergic systems by psilocybin
and ketamine may change emotional processing biases as
indexed by the assessment of visual evoked responses to
emotional expressions.
Recent studies used event-related potential (ERP) record-
ing to investigate the time course of non-conscious and con-
scious emotional face processing (Pegna et al. 2011; Smith
2011). Studies of ERPs generated by faces often focus on key
components such as the P100 and the face-sensitive N170.
The P100 is an early positive occipital potential, peaking at
around 80–120 ms post-stimulus, and reflects rapid extraction
of information related to emotion or salience that occurs
before more fine-grained perceptual analyses are completed
(Vuilleumier and Pourtois 2007). Modulation of the P100 has
been shown with fearful (Fichtenholtz et al. 2009; Pourtois
and Vuilleumier 2006), angry (Santesso et al. 2008) and
positive expressions (Batty and Taylor 2003; Brosch et al.
2008). The N170 is a negative occipitotemporal potential at
approximately 170 ms post-stimulus and is associated with
structural encoding of facial configurations (Itier and Taylor
2004; Rossion and Jacques 2008). The view that the N170
ERP is not modulated by the emotional content of faces
(Ashley et al. 2004; Eimer and Holmes 2002; Krolak-
Salmon et al. 2001) has been challenged by other findings
(Batty and Taylor 2003; Blau et al. 2007; Jaworska et al. 2010;
Krombholz et al. 2007; Schyns et al. 2007; Sprengelmeyer
and Jentzsch 2006; Stekelenburg and de Gelder 2004), even
when faces are non-consciously processed (Pegna et al. 2008;
Smith 2011). Thus, the N170 reflects not only face sensitivity
but also emotion sensitivity during conscious as well as non-
conscious face processing. Furthermore, it has been shown
that the N170 amplitude correlates with the severity of de-
pressive symptoms (Noll et al. 2012), while both the P100 and
N170 amplitudes are significantly differed between
healthy volunteers and subjects with bipolar disorder
(Degabriele et al. 2011; Sokhadze et al. 2011). These
studies together demonstrate the potential of these ERPs
to study pharmacological mechanisms underlying emo-
tional biases and their pathophysiology.
In this study, we assessed these ERPs to compare the
effects of the glutamate NMDA receptor antagonist ket-
amine and the 5-HT receptor agonist psilocybin on visual
processing stages during emotional face processing. Nota-
bly, both ketamine and psilocybin are suggested to modulate
neuronal activity in circuits implicated in emotion regulation
and to have implications for the treatment of affective dis-
orders. While it has repeatedly been pointed out that acute
ketamine administration ameliorates depressive symptoms
in treatment-resistant depression within a few hours persist-
ing for several days (Diazgranados et al. 2010; Zarate et al.
2006), a gradual reduction in trait anxiety at 1 and 3 months,
as well as in depressive symptoms at 6 months, was ob-
served after a single dose of psilocybin in terminal cancer
and anxiety patients (Grob et al. 2011). Based on these
findings, in this paper we hypothesized that manipulations
of both the NMDA and 5-HT receptor system using ket-
amine and psilocybin may inhibit negative face processing
and facilitate the processing of positive faces as expressed
by modulations of the P100 and N170 ERP. Given that
visual responses are modulated by face visibility (Pessoa
et al. 2006), we further predicted that both drug effects on
the visual ERPs might vary between non-conscious and
conscious face processing. Thus, to test our hypothesis, we
examined on the one hand whether psilocybin and ketamine
affect visual ERP responses to emotional faces in a valence
specific manner and on the other hand whether these drug
effects depend on visual awareness.
Method
Participants
Healthy subjects were recruited through advertisement
from the local universities and were then separated into
two groups (S-ketamine group: N021 [male, 12], mean
age026±5.39 years; psilocybin group: N021 [male, 13],
mean age023±2.22 years, all were students). Subjects
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were healthy according to medical history, clinical ex-
amination, electrocardiography, and blood analysis. Sub-
jects were screened by the DIA-X diagnostic expert
system (Wittchen and Pfister 1997), a semi-structured
psychiatric interview to exclude those with personal or
family (first-degrees relatives) histories of major psychi-
atric disorders, and by the Symptom Checklist (SCL-
90–R) (Derogatis 1994). Furthermore, subjects replied to
the Mini-International Neuropsychiatric Interview, a brief,
structured psychiatric interview (Sheehan et al. 1998). No
subjects had to be excluded using these criteria. We verified
the absence of a history of drug dependence by urine drug-
screening and a self-made consumption questionnaire. In the
S-ketamine group, seven subjects were occasional smokers
(<10 cigarettes/day), eight subjects reported a sporadic or rare
cannabis use in the past (<3 joints/month), two subjects
reported experiences with MDMA (three pills lifetime),
two subjects had previous LSD experiences (5 lifetime
experiences), and one subject reported having previous
experiences with ketamine (one occasions lifetime). In
the psilocybin group, eight subjects were occasional smok-
ers (<6 cigarettes/day), eight subjects reported a sporadic or
rare cannabis use in the past (<2 joints/month), one subject
reported experiences with MDMA (two pills lifetime), two
subjects had prior use histories of ingesting psilocybin
containing mushrooms (two lifetime experiences), and
one subject reported experiences with LSD (two lifetime
experiences). All subjects were free of any medication for at
least 3 weeks before the experiment.
This study was approved by the Ethics Committee of the
University Hospital of Psychiatry in Zurich. After receiving
a written and oral description of the aim of this study, all
participants gave written informed consent statements be-
fore inclusion. The use of psilocybin was authorized by the
Swiss Federal Office for Public Health, Department of Phar-
macology and Narcotics, Berne, Switzerland.
Drug administration
In both groups, subjects underwent two sessions (placebo/
active drug) in a counterbalanced and double-blind fashion
at an interval of at least 2 weeks. Subjects were monitored
until all drug effects had worn off and were then released
into the custody of a partner. For the S-ketamine/placebo
infusion, an in-dwelling catheter was placed in the antecu-
bital vein of the nondominant arm. Once the subject was
ready, a bolus injection of 10 mg over 5 min was given.
Following a 1-min break, a continuous infusion with
0.006 mg/kg/min was administered over 80 min. To keep
S-ketamine’s plasma level fairly constant, the dose was
reduced every 10 min by 10 % as previously described
((Feng et al. 1995; Vollenweider et al. 1997). In the placebo
session, the same procedure was followed and an infusion of
physiological sodium chloride solution and 5 % glucose was
given. Psilocybin (115 μg/kg) and lactose placebo were
orally administered in gelatin capsules of identical number
and appearance as previously described in studies assessing
the acute psychological and physiological effects of psilo-
cybin in healthy humans (Hasler et al. 2004; Studerus et al.
2011). Psilocybin was orally given not only to ensure direct
comparability with these previous studies and external va-
lidity but also to induce stabile psychological effects after
60–90 min post-treatment, lasting for 60–120 min (Hasler et
al. 2004). Furthermore, given the putative therapeutic po-
tential of psilocybin (Kometer et al. 2012; Vollenweider and
Kometer 2010; Grob et al. 2011), an oral dosing regimen
provides a more personable setup than utilizing an intravenous
dosing regime for psilocybin.
Psychological assessment
The Altered State of Consciousness (ASC) questionnaire, a
visual analog and self-rating scale, was used to assess the
subjective psychological effects induced by S-ketamine and
psilocybin (Dittrich 1975, 1998). A recent evaluation study of
the ASC questionnaires has constructed 11 new lower-order
scales (Studerus et al. 2010), which were assessed in this
study. After the acute effects of S-ketamine (about 240 min
post-treatment) and psilocybin (about 360 min after treatment)
had subsided, the ASC questionnaire was given to retrospec-
tively rate their introspective experiences since drug intake.
Stimuli and backward masking procedure
As stimulus material, we took black and white photographs
taken from the Ekman–Friesen series (Ekman and Friesen
1976). In order to exclude the hair and non-facial contours
and further to match for luminance and contrast, each face was
modified using Adobe Photoshop as previously done in other
studies (Blau et al. 2007; Pegna et al. 2008; Pourtois et al.
2004). The final facial images subtended a visual angle of 3°
horizontally and 4.4° vertically and were displayed in the
center of a CRT monitor (refresh rate of 100 Hz). Subjects
first underwent a mismatch negativity event-related paradigm
for 15 min, which has been published elsewhere (Schmidt et
al. 2011). Emotional measures using backward masking para-
digms were started 25 min after S-ketamine infusion and
110 min following psilocybin administration during the
known plateau (Hasler et al. 2004; Passie et al. 2002).
Backward masking paradigms (facial affect discrimina-
tion and EEG/ERP recording) were generated by a software
dedicated to psychological testing (E-prime; Schneider et al.
2002). Backward masking is a key experimental paradigm for
investigating sensory unawareness because this method inter-
feres with the activity in the ventral occipitotemporal cortex,
an area which is highly relevant for visual awareness
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(Tamietto and de Gelder 2010). The accuracy of stimulus
duration was confirmed using an oscilloscope. Figure 1 shows
the backward making procedures for the facial discrimination
task (A) and for the subsequent EEG/ERP recording (B).
Facial affect discrimination Two discrimination tasks were
conducted to establish thresholds for visual awareness in all
drug conditions, i.e., to determine the time point, at which
subjects can distinguish emotional from neutral expression
above chance level. In a first task, subjects had to discrim-
inate fearful from neutral faces, while in a second task they
had to discriminate happy from neutral faces. For each
discrimination task, target faces consisted of neutral and
fearful/happy faces and were presented for 20, 30, 50, 90,
or 170 ms (Williams et al. 2004). Target faces were imme-
diately followed by a neutral mask of the same person
lasting for 150 ms. Participants performed five blocks of
40 trials (target–mask pairs) for each of both tasks, in which
target faces were randomly presented with equal probability.
Before the presentation of target–mask pairs, a fixation cross
was presented for 1,000 ms. Subjects had to make a forced-
choice decision about the valence of the target face (fearful/
happy vs. neutral) via button-press.
EEG/ERP recording During subsequent ERP recording,
stimuli were identical to those used during the facial affect
discrimination. Target faces comprised neutral, fearful, and
happy faces and were immediately followed by a neutral mask
of the same person for 150 ms. Each trial began with a fixation
cross that lasted for 2,000 ms. According to the results of the
discrimination tasks, target faces were 10 ms presented during
non-conscious processing and 200 ms during conscious
processing. No subject response (button-press) was required.
However, participants were given instructions that pairs of
target–mask faces would be presented and that they would
be asked questions about the first faces after testing.
Event-related potential recording
EEG recordings were made from 64 scalp electrodes using the
ActiveTwo system (Biosemi, the Netherlands). The horizontal
electroocculogram (EOG) was recorded from electrodes at-
tached on the outer canthus of each eye. Similarly, vertical
EOG was recorded from electrodes attached infraorbitally and
supraorbitally to the left eye. All electrodes were active silver/
silver chloride electrodes and the offset of all electrodes was
below 25 mV. Data were recorded at a sampling rate of
512 Hz. The common mode sense active electrode and the
driven right leg passive electrode were used as reference and
ground electrodes, respectively (see http://www.biosemi.com/
faq/cms&drl.htm for more details on this setup).
For ERP analysis, independent component analysis was
used to remove artifacts due to eye movements and blinks
(Lee et al. 1999). The EEG data were recalculated offline
against average reference. Then, epochs with a 200-ms pres-
timulus baseline and a 500-ms post-stimulus interval were
constructed. Epochs with amplitudes that exceeded ±100 μV
at any electrode were excluded from further averaging. After
artifact rejection, epochs were averaged for each subject and
were digitally filtered with a band-pass filter (1–30 Hz). P100
and N170 ERPs were computed at electrodes P08/P8/P10/O2
(right hemisphere) and PO7/P7/P9/O1 (left hemisphere) as
peak positivity/negativity relative to baseline within the
130–200- and 150–250-ms window latency, respectively, as
Fig. 1 Schematic of the
backward masking paradigms.
During the discrimination
threshold tasks (a), a fixation
cross was first presented for
1,000 ms, followed by the
target face, which lasted for 20,
30, 50, 90, or 170 ms,
respectively. Finally, a neutral
mask of the same person was
presented for 150 ms. After
each target–mask pair, subjects
were asked to answer via key
press. During ERP recording
(b), the fixation cross was
presented for 2,000 ms. The
presentation time for the target
faces was 10 ms for non-
conscious processing and
200 ms for conscious
processing
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previously described (Frühholz et al. 2011; Jaworska et al.
2010; Wronka and Walentowska 2011).
Statistical analysis
Discrimination performances were analyzed according to sig-
nal detection theory, which provides a measure of sensitivity
that is independent of subject’s response bias (Macmillan and
Creelman 1991). This procedure avoid potential limitations of
subjective self-report performances, in which subjects report
no visual awareness but may nonetheless experience some
level of awareness (Bernat et al. 2001). Threshold settings
were determined by Student’s t tests against chance level
(sensitivity indexes of d′00). D’s were further subjected to a
repeated measurement analysis of variance (ANOVA) with the
within-subject factors target duration (20, 30, 50, 90, 170 ms),
valence (fearful, happy), and treatment (placebo, drug), as well
as with the between-subject factor group (S-ketamine, psilo-
cybin). In a first step, P100 and N170 ERP data were sepa-
rately analyzed for the S-ketamine and psilocybin group by
repeated measurement ANOVAs with the within-subject fac-
tors treatment (placebo, S-ketamine, or psilocybin), target du-
ration (non-conscious, conscious), valence (fearful, happy, and
neutral), and laterality (right, left). To further compare both
drug effects on the specific ERP, in a second step, we comput-
ed the change scores between the placebo and both drug
conditions (placebo−drug). Change scores were subjected to
a repeated-measures ANOVA with the within-subject factors
target duration (non-conscious, conscious), valence (fearful,
happy, and neutral), and laterality (right, left) and with the
between-subject factor group (S-ketamine, psilocybin). Re-
peated measurement ANOVA on the ASC data with treatment
and scale as within-subject factors and group as between-
subject factor was used to examine drug-induced psychologi-
cal effects. Where the ANOVA null hypotheses of equal means
were rejected, we used Fisher’s least significant difference tests
(LSD) for post hoc testing. For further analysis, we computed
the average of the d′ change score (d′ pla−d′ drug) over all
target durations as indexed by “d′ fear” and “d′ happy.” Given
that the activity in face-sensitive areas within the visual cortex
increases gradually with subjective rating of recognition suc-
cess (Bar et al. 2001), we used linear regression analysis to
examine the relationship between discrimination success (i.e.,
d′ fear and d′ happy) and N170 changes scores.
Results
Facial affect discrimination
Student’s t tests against d′00 revealed that for the discrim-
ination of fearful relative to neutral faces (Fig. 2), d′ at 20 ms
under placebo did not significantly differ from chance level
(S-ketamine group: mean d′00.05, SD00.31, p00.5;
psilocybin group: mean d′00.1, SD00.35, p00.19),
while d′ at 30 ms became significantly above chance
level (S-ketamine group: mean d′00.30, SD00.29) (p<
0.0001; psilocybin group: mean: d′00.36, SD00.63, p<
0.05). In contrast, under the influence of both drugs, d′s
at 30 ms were still not above chance level (S-ketamine
group: mean d′00.12, SD00.67, p00.42; psilocybin
group: mean d′00.04, SD00.7, p00.81), whereas per-
formances at 50 ms reached significance (S-ketamine
group: mean d′00.36, SD00.37, p’s<0.001; psilocybin
group: mean d′00.20, SD00.33, p<0.05). During the
discrimination of happy faces (Fig. 3), d′ values for
each duration time in all drug conditions significantly
varied from chance level.
Independent of threshold setting, repeated-measures
ANOVA over both groups revealed that d′ significantly
increased across target duration [F(4,160)0195.19; p<
0.00001; η2p 00.83]. In general, d′ values for happy faces
were significantly higher than for fearful faces (p<0.05) as
indicated by a significant main effect for valence [F(1,40)0
4.15; p<0.05; η2p 00.09]. Furthermore, a significant main
effect for treatment was found [F(1,40)036.04; p<0.00001;
η2p00.47]. Particularly, a treatment×valence×group interac-
tion [F(1,40)04.11; p<0.05; η2p 00.09] revealed that S-
ketamine significantly reduced d′ for both fearful (p<
0.001) and happy faces (p<0.001) relative to placebo, while
psilocybin exclusively reduced d′ for fearful (p<0.001) but
not for happy faces (p00.87).
Event-related potential responses
Mean of grand averages over both hemisphere of the P100
and N170 ERP during non-conscious and conscious pro-
cessing are shown in Fig. 4.
P100 event-related potential
Repeated-measures ANOVA on the P100 amplitudes
revealed generally more pronounced P100 amplitudes over
right compared to left electrodes in both the S-ketamine [F
(1,20)018.23; p<0.001; η2p00.48] and the psilocybin group
[F(1,20)022.22; p<0.001; η2p 00.53]. However, no treat-
ment effects were observed for the P100 amplitudes in the
psilocybin [F(1,20)00.099; p00.13; η2p03.00] and-ketamine
group F(1,20)00.011; p<0.917; η2p00.001]. Comparing the
effect of S-ketamine and psilocybin, repeated-measures
ANOVA on the change scores for the P100 amplitude
showed no main effects and interactions, reflecting an equal
influence of S-ketamine and psilocybin on the P100
amplitude.
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N170 event-related potential
Repeated-measures ANOVA on the S-ketamine data
revealed that N170 amplitudes were generally more pro-
nounced over right compared to left electrodes and more
pronounced for emotional relative to neutral faces, as indi-
cated by a significant main effect for laterality (F(1,20)0
25.97; p<0.0001; η2p00.56) and valence (F(2,40)05.47; p<
0.01; η2p00.21). Furthermore, a main effect of treatment was
found (F(1,20)08.73; p<0.01; η200.30), reflecting the
overall N170 reduction under S-ketamine. The treatment×
laterality interaction (F(1,20)046.70; p<0.00001; η2p 00.71)
showed that the treatment effect occurred only over right
electrodes (p<0.000001) (Fig. 5, left), but not over left elec-
trodes (p00.14). In general, the S-ketamine effect on the N170
amplitude was more pronounced during conscious (p<
0.00001) (mean difference −1.1 μV) than non-conscious pro-
cessing (p<0.001) (mean difference −0.6 μV), indicated by
Fig. 2 Sensitivity indices (d′)±
SE represented as a function of
target duration during fear
discrimination. Notably, both S-
ketamine and psilocybin signif-
icantly reduced d′ values for
fearful relative to neutral faces
Fig. 3 Sensitivity indices (d′)±
SE represented as a function of
target duration during the
discrimination of happy faces.
Notably, S-ketamine but not
psilocybin significantly reduced
d′ values for happy relative to
neutral faces
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treatment×target duration interaction (F(1,20)04.75; p<0.05;
η2p00.19). No treatment×valence interaction was found for S-
ketamine on the N170 (F(1,20)01.88; p00.1.66; η2p00.086).
Repeated-measures ANOVA on the psilocybin data
revealed significant main effects for laterality (F(1,20)0
39.43; p<0.00001; η2p00.66) and treatment (F(1,20)014.21;
Fig. 4 Mean of grand averages over both hemispheres of the P100 and
N170 ERP for fearful (a), neutral (b), and happy faces (c) during non-
conscious (left) and conscious processing (right) following placebo
(solid line), S-ketamine (Ket: dashed line), and psilocybin (Psi: dotted
line) administration, respectively
Fig. 5 Mean N170 amplitudes±
SE over right electrodes for
fearful, neutral, and happy faces
under S-ketamine (red line), psi-
locybin (blue), and placebo
(green). Note: Significant differ-
ences between treatment condi-
tions at *p<0.01 and at
**p<0.00001
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p<0.01; η2p 00.42), reflecting the more pronounced re-
sponse over right relative to left electrodes (p<0.00001) and
the general N170 reduction induced by psilocybin (p<0.01).
This treatment effect was found only over right electrodes (F
(1,20)06.61; p<0.05; η2p 00.25). The main effect of valence
indicated the more pronounced N170 amplitude for
emotional compared to neutral faces (F(2,40)09.79; p<
0.001;η2p00.33). Furthermore, the laterality×treatment×target
duration interaction (F(1,20)04.52; p<0.05; η2p 00.18)
revealed that the N170 effect over right electrodes was
more pronounced during conscious (p<0.000001) (mean
difference −1.38 μV) than non-conscious processing (p<
0.01) (mean difference −0.71 μV). Finally, as shown by a
significant treatment×valence interaction (F(2,40)05.92;
p<0.01; η2p 00.23), psilocybin significantly reduced the
N170 amplitudes in response to fearful (p<0.000001)
and neutral faces (p<0.01), but not to happy faces
(p00.1) (Fig. 5, right).
Comparing the S-ketamine and psilocybin effects on the
N170, repeated-measures ANOVA on the change scores
revealed significant main effects for target duration (F(1,
40)06.53; p<0.05; η2p00.14) (F(1,40)06.53; p<0.05; η
2
p0
0.14), laterality (F(1,40)034.29; p<0.00001; η2p00.46), and
valence (F(2,80)05.15; p<0.01; η2p 00.11). LSD post hoc
testing revealed that in general both drug effects were more
pronounced over right than left electrodes (p<0.00001) and
more pronounced during conscious than non-conscious pro-
cessing (p<0.05). Most intriguingly in regard to the contri-
bution of glutamate and serotonin to emotional processing, a
laterality×valence×group interaction was found (F(2,80)0
4.02; p<0.05; η2p 00.09). Particularly, although S-ketamine
and psilocybin equally modulated the N170 amplitudes in
response to fearful (p00.78) and neutral faces (p00.82) over
right electrodes, happy faces were differentially modulated
by S-ketamine and psilocybin (p<0.05) (Fig. 6).
Finally, we asked whether the drug-induced changes in
the behavioral performances (d′ fear and d′ happy) might be
explained through the drug effects on the N170 over right
electrodes using linear regression analysis. For both groups,
we found no significant relations between d′ fear and N170
change score for fearful faces (psilocybin group: F00.28,
p00.757; S-ketamine group: F02.23, p00.136), as well as
between d′ happy and N170 change score for happy
faces (psilocybin group: F01.25, p00.311; S-ketamine
group: F00.974, p00.397).
Psychological assessment
Both S-ketamine and psilocybin produced similar altera-
tions on the global ASC scores (Fig. 7). Repeated-
measures ANOVA on the ASC data showed significant main
effects for treatment (F(1,40)080.99; p<0.00001; η2p 00.67)
and scale (F(11,440)09.73; p<0.000001; η2p00.20). A triple
treatment×scale×group interaction indicated significant dif-
ferences between both drug effects on specific scales [F(11,
440)05.35; p<0.00001; η2p 00.12]. Post hoc testing showed
that S-ketamine increased all scales relative to placebo (p’s<
0.01), expect for anxiety (p00.09), while psilocybin increased
all scales (p’s<0.01), expect for auditory alterations (p00.42)
and anxiety (p00.36). Moreover, LSD post hoc analysis
showed that S-ketamine produced significantly higher
scores than psilocybin for disembodiment (p<0.000001),
auditory alterations (p<0.05), and for impaired control and
cognition (p<0.05). Otherwise, psilocybin produced more
pronounced visual illusions and elementary hallucinations
than S-ketamine as indexed by the elementary imagery
score (p<0.01).
Discussion
In this paper, we present a suitable approach to compare
glutamatergic and serotonergic effects on emotional face
processing. Specifically, according to the firstly assessed
discrimination thresholds, we used event-related potential
recording to investigate the effect of the NMDA receptor
antagonist S-ketamine and the 5-HT receptor agonist psilo-
cybin either on conscious or non-conscious emotional face
processing. Our study provide three major results: Firstly,
the structural encoding of facial configurations as expressed
by the N170 ERP is impaired by S-ketamine and psilocybin,
while the fast extraction of visual emotion-related informa-
tion (i.e., P100 ERP) is not affected by both drugs. Second-
ly, the N170 ERP is differentially modulated by S-ketamine
and psilocybin. Although both drugs reduce the N170 ERP
responses to fearful faces, the structural encoding of happy
faces is only impaired by S-ketamine. Finally, both drug
effects on the N170 ERP are more pronounced during
conscious than non-conscious processing. In the follow-
ing, we discuss our results and consider their potential
implications.
On the behavioral level, regardless of threshold setting,
S-ketamine and psilocybin differentially affected facial dis-
crimination performances. Particularly, the subjective ability
to discriminate fearful from neutral face identities was im-
paired following both S-ketamine and psilocybin adminis-
tration. In contrast, the discrimination performance of happy
relative to neutral faces was only affected by S-ketamine but
not by psilocybin, suggesting that the effect of psilocybin is
valence specific on the behavioral level.
On the electrophysiological level, the N170 amplitude
was more pronounced for emotional relative to neutral faces
in both groups without any drug intake (i.e., under placebo),
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reflecting an emotional face processing bias as previously
reported (Blau et al. 2007; Jaworska et al. 2010; Krombholz
et al. 2007; Pegna et al. 2008; Schyns et al. 2007; Smith
2011). Psilocybin impaired the structural encoding of fearful
faces as expressed by reduced N170 responses to fearful
faces, while no psilocybin-induced N170 alteration in re-
sponse to happy faces was found in this study. Thus, psilo-
cybin shifted the negative N170 processing bias seen under
placebo. These findings differ from previous studies report-
ing that the SSRI citalopram does not acutely modulate the
N170 ERP in response to emotional faces in healthy sub-
jects (Kerestes et al. 2009; Labuschagne et al. 2010), where-
as later ERPs such as the N250 or the LPP, which have been
associated with “expression decoding,” are modulated by
citalopram (Kerestes et al. 2009; Labuschagne et al. 2010).
Beyond methodological differences across these studies
such as the use of the reference electrodes, the differential
effect of psilocybin and citalopram on the N170 ERP may
be due to the different pharmacological effects of psilocybin
and citalopram on the 5-HT system. While citalopram over-
all increases 5-HT brain levels (Elliott et al. 2011; Nutt et al.
1999), psilocin, the active metabolite of psilocybin, is an
agonists at 5-HT receptors which binds with high affinity
specifically at 5-HT1, HT2, and 5-HT6 receptors (Nichols
2004). That the different pharmacological profiles of psilo-
cybin and citalopram on the 5-HT system may be most
Fig. 7 Effects of S-ketamine
(dashed line) and psilocybin
(dotted line) on the ASC scales.
Mean scores and ±SE (both
n021). Note: *p<0.05, **p<
0.01, and ***p<0.000001 indi-
cate significant differences be-
tween drugs. Symptoms scores
were expressed as percent of
scale maximum
Fig. 6 Mean change scores of
N170 ERP±SE as a function of
face valence over right parieto-
occipital electrodes. Notably, the
N170 ERP reduction for fearful
and neutral faces was compara-
ble among both drugs, but the
N170 ERP for happy faces was
significantly more reduced after
S-ketamine (circle) than psilocy-
bin exposure (triangle). *p<0.05
indicates a significant difference
between the effect of S-ketamine
and psilocybin on happy faces
Psychopharmacology (2013) 225:227–239 235
critical in mediating their N170 effects on emotional face
processing is further supported by the finding that decreas-
ing brain 5-HT levels by acute tryptophan depletion (ATD)
did not affect the N170 during face processing as well
(Jaworska et al. 2010). Along this line, the P100 ERP is
also differently altered by psilocybin and ATD. Particularly,
while ATD enhances the P100 for sad versus joyful faces
(Jaworska et al. 2010), in this study no P100 alteration to
facial expressions was found under psilocybin. Thus, the
sensitivity of the P100 and N170 ERP may differentially
depend on 5-HT brain levels and the activation of a set of
different 5-HT receptors subtypes.
Discussing the effect of S-ketamine on the visual ERPs,
the only work with reference to our result is a previous fMRI
study, which explored the functional network following ket-
amine administration during emotional face processing
(Abel et al. 2003). The key finding of this study was that
the amygdala and fusiform gyrus (FG) activity in response
to fearful faces under placebo was abolished following ket-
amine administration. The authors suggested that this
ketamine-induced effect on limbic and visual regions is
associated with the emotional blunting and depersonaliza-
tion phenomena that are evident in ketamine states (Krystal
et al. 1994; Vollenweider et al. 1997). Such an interpretation
is consistent with the present finding that S-ketamine re-
duced the N170 ERP not only in response to fearful but also
to neutral and happy faces, reflecting an overall emotional
blunting of visually induced neural responses.
According to several source localization studies (Deffke
et al. 2007; Rossion et al. 2003; Sadeh et al. 2010), the
generators of the N170 ERP have been localized to the FG,
which encodes the structural configuration of facial features.
The significance of structural information encoding in visual
perception is shown by a functional relationship between
object discrimination performance and FG activity. In par-
ticular, a previous study found that FG activity increases
gradually with subjective rating of recognition success (Bar
et al. 2001). An identical relationship was also suggested
following citalopram administration in healthy subjects
(Harmer et al. 2003). It has been proposed that the enhanced
fear detection in healthy subjects treated with citalopram
(Harmer et al. 2003) may be partly due to an increased
activity in the FG (Del-Ben et al. 2005). Albeit not statisti-
cally underpinned, we observed that both drug effects on the
subjective discrimination performances correspond approx-
imately to the electrophysiological changes on the N170
following drug administration (cf. Figs. 2, 3, and 5).
These findings suggest that the relationship between
discrimination success and FG activity/N170 amplitude
might remain following manipulation of the 5-HT and
NMDAR system. However, the lack of a statistical
significance warrants further investigations to strengthen
this relationship.
Neurofunctionally, increased visual evoked responses to
relevant emotional expressions are likely mediated via rich
interconnections between the FG and the amygdala (Amaral
et al. 2003; Freese and Amaral 2005), the coupling of which
is additionally strengthened during attentive viewing of
affective faces (Fairhall and Ishai 2007; Herrington et al.
2011). Furthermore, emotional face processing also involves
prefrontal areas, which are functionally connected with the
FG and the amygdala (Dima et al. 2011). Critically, both S-
ketamine and psilocybin were found to deactivate limbic
and to increase prefrontal neural activity during resting
states in healthy subjects (Vollenweider and Kometer
2010). Thus, it is arguable that the psilocybin- and S-
ketamine-induced N170 effects in response to fearful faces
may be due to functional alterations in the amygdala-
prefrontal network. However, why psilocybin and S-
ketamine had dissociable effects on happy face processing
is difficult to derive from the present data. A possible
explanation could be that S-ketamine and psilocybin differ-
entially modulate circuitries responsible for the processing
of positive expressions because the processing of positive
information such as happy faces also involves reward-
related areas (Adolphs 2003; Ishai 2007; Singer et al.
2004) relative to the processing of negative information
and further because the N170 showed priming effects as a
function of reward (Marini et al. 2011). However, this is
highly speculative at the present time.
Another key finding of this study was further that the
psilocybin- and S-ketamine-induced N170 effect was more
pronounced during conscious than non-conscious visual
processing independent of the face expression. This finding
fits with the assumption that the N170 is associated with
perceptual consciousness of the face (Rossion and Jacques
2008) and that FG responses are modulated by the level of
target visibility (Pessoa et al. 2006; Pessoa and Padmala
2005). Furthermore, numerous studies have described an
increase of the N170 ERP with selective attention (Gazzaley
et al. 2005; Wronka and Walentowska 2011), suggesting
top-down attentional control. In particular, the visual cortex
receives top-down modulation from frontal and parietal
areas in relation to visual attention (Bressler et al. 2008) in
the time range of the N170 ERP (Rose et al. 2005). In this
view, several studies reported that psilocybin attenuates
attentional performances (Carter et al. 2005; Gouzoulis-
Mayfrank et al. 2002; Quednow et al. 2011). A recent study
examining the influence of psilocybin on the spatiotemporal
dynamics of object completion and found a dose-dependent
reduction of the N170 ERP response (Kometer et al. 2011).
The authors suggested that this reduction might reflect a
psilocybin-induced failure to allocate attention. Similarly,
previous evidence revealed that ketamine produce cognitive
deficits including impairments of attention (Morgan et al.
2004; Newcomer et al. 1999). Therefore, we suggest that the
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more pronounced effects of psilocybin and S-ketamine on
the N170 during conscious relative to non-conscious pro-
cessing indicate a drug-induced reduction of attentional
resources. One point of contention, however, may be that
there is some evidence of conscious perception of happy
faces with 20 ms in this study. This means that we cannot
infer from the discrimination threshold task that 10 ms is
truly non-conscious for the processing of happy faces. How-
ever, recent ERP studies confirmed presentation times be-
low 20 ms for non-conscious processing of happy faces
(Balconi and Lucchiari 2008; Pegna et al. 2011; Smith
2011). Therefore, it is conceivable to assume that presenta-
tion times of 10 ms as used in our ERP experiment are really
non-conscious also for the processing of happy faces.
Summarized, this study demonstrated that the NMDA
and 5-HT receptor systems differentially contribute to the
structural encoding of emotional face expressions as
expressed by the N170 event-related potential. Our findings
confirm the emotion sensitivity of the N170 ERP during
conscious and non-conscious face processing as recently
reported (Pegna et al. 2008; Smith 2011) and further suggest
that the assessment of early visual evoked responses might
allow detecting pharmacologically induced change in emo-
tional processing biases and provides thus a suitable frame-
work to study pathophysiological mechanisms underlying
dysfunctional emotional biases.
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